Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2007 Oct 17;2007(4):CD003167.
doi: 10.1002/14651858.CD003167.pub3.

Medical interventions for primary open angle glaucoma and ocular hypertension

C Vass  1 , C Hirn, T Sycha, O Findl, P Bauer, L Schmetterer
Affiliations
Meta-Analysis

Medical interventions for primary open angle glaucoma and ocular hypertension

C Vass et al. Cochrane Database Syst Rev. .

Abstract

Background: Primary open angle glaucoma (POAG) is a progressive optic neuropathy with an elevated intraocular pressure (IOP), where the optic nerve head becomes pathologically excavated and the visual field (VF) is characteristically altered. Ocular hypertension (OHT) is a condition with elevated IOP but without discernible pathology of the optic nerve head or the VF. It is a major risk factor for development of POAG.

Objectives: To assess and compare the effectiveness of topical pharmacological treatment for POAG or OHT to prevent progression or onset of glaucomatous optic neuropathy.

Search strategy: We searched CENTRAL, MEDLINE and EMBASE in May 2007. We searched the bibliographies of identified articles and contacted experts, investigators and pharmaceutical companies for additional published and unpublished studies.

Selection criteria: Randomised controlled trials comparing topical pharmacological treatment to placebo, no treatment or other treatment for specified endpoints which included people with POAG or OHT, and with duration of treatment of at least one year.

Data collection and analysis: Two authors independently extracted data and assessed trial quality. Where appropriate, we summarised data using Peto odds ratio and mean difference after testing for heterogeneity between studies.

Main results: We included 26 trials, which randomised 4979 participants, in this review. Meta-analysis of 10 trials clearly demonstrated reduction of onset of VF defects in treated OHT (OR 0.62, 95% CI 0.47 to 0.81). No single drug showed a significant VF protection compared to placebo or untreated controls. We did identify some border line evidence for a positive influence of treatment on VF prognosis (OR 0.67, 95% CI 0.45 to 1.00) for the beta-blockers .

Authors' conclusions: The results of this review support the current practice of IOP lowering treatment of OHT. A visual field protective effect has been clearly demonstrated for medical IOP lowering treatment. Positive but weak evidence for a beneficial effect of the class of beta-blockers has been shown. Direct comparisons of prostaglandins or brimonidine to placebo are not available and the comparison of dorzolamide to placebo failed to demonstrate a protective effect. However, absence of data or failure to prove effectiveness should not be interpreted as proof of absence of any effect. The decision to treat a patient or not, as well as the decision regarding the drug with which to start treatment, should remain individualised, taking in to account the amount of damage, the level of IOP, age and other patient characteristics.

PubMed Disclaimer

Conflict of interest statement

None known.

Figures

1.1
1.1. Analysis
Comparison 1 Beta‐blockers versus placebo or untreated, Outcome 1 Incidence of visual field defect progression.
1.2
1.2. Analysis
Comparison 1 Beta‐blockers versus placebo or untreated, Outcome 2 Drop‐out due to drug‐related adverse events.
1.3
1.3. Analysis
Comparison 1 Beta‐blockers versus placebo or untreated, Outcome 3 Sensitivity analysis concerning the incidence of visual field defect progression.
1.4
1.4. Analysis
Comparison 1 Beta‐blockers versus placebo or untreated, Outcome 4 Long‐term studies concerning the incidence of visual field progression.
2.1
2.1. Analysis
Comparison 2 Comparison of timolol and carteolol, Outcome 1 Incidence of visual field defect progression.
3.1
3.1. Analysis
Comparison 3 Comparison of timolol and levobunolol, Outcome 1 Incidence of visual field defect progression.
3.2
3.2. Analysis
Comparison 3 Comparison of timolol and levobunolol, Outcome 2 Drop‐out due to drug‐related adverse events.
4.1
4.1. Analysis
Comparison 4 Comparisons of timolol and betaxolol, Outcome 1 Change of visual field mean sensitivity.
4.2
4.2. Analysis
Comparison 4 Comparisons of timolol and betaxolol, Outcome 2 Drop‐out due to drug‐related adverse events.
5.1
5.1. Analysis
Comparison 5 Comparison of timolol and brimonidine, Outcome 1 Incidence of visual field defect progression.
5.2
5.2. Analysis
Comparison 5 Comparison of timolol and brimonidine, Outcome 2 Drop‐out due to drug‐related adverse events.
6.1
6.1. Analysis
Comparison 6 All treatments versus placebo or untreated, Outcome 1 Incidence of visual field defect progression.
6.2
6.2. Analysis
Comparison 6 All treatments versus placebo or untreated, Outcome 2 Sensitivity analysis concerning the incidence of visual field progression.
6.3
6.3. Analysis
Comparison 6 All treatments versus placebo or untreated, Outcome 3 Sensitivity analysis concerning the incidence of visual field progression; without OHTS study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD003167.pub2

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Alexander 1988 {published data only}
    1. Alexander DW, Berson FG, Epstein DL. A clinical trial of timolol and epinephrine in the treatment of primary open‐angle glaucoma. Ophthalmology 1988;95(2):247‐51. - PubMed
Collignon‐Brach 1992 {published data only}
    1. Collignon‐Brach J. Long‐term effect of ophthalmic beta‐adrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open‐angle glaucoma. Current Eye Research 1992;11(1):1‐3. - PubMed
Collignon‐Brach 1994 {published data only}
    1. Collignon‐Brach J. Longterm effect of topical beta‐blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open‐angle glaucoma. Survey of Ophthalmology 1994;38(Suppl 1):S149‐55. - PubMed
Drance 1998 {published data only}
    1. Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open‐angle glaucoma. Journal of Glaucoma 1998;7(4):247‐52. - PubMed
EGPS 2005 {published data only}
    1. The European Glaucoma Prevention Study. The European glaucoma prevention study design and baseline description of the participants. Ophthalmology 2002;109(9):1612‐21. - PubMed
    1. The European Glaucoma Prevention Study Group. Results of the European glaucoma prevention study. Ophthalmology 2005;112(3):366‐75. - PubMed
Epstein 1989 {published data only}
    1. Epstein DL, Krug JH, Hertzmark E, Remis LL, Edelstein DJ. A long‐term clinical trial of timolol versus no treatment in the management of glaucoma suspects. Ophthalmology 1989;96(10):1460‐7. - PubMed
Fama 1996 {published data only}
    1. Fama F, Santamaria S. Comparison of the ocular effects of three beta‐blockers: timolol, carteolol, and betaxolol. Annals of Ophthalmology 1996;28(5):317‐20.
Flammer 1992 {published data only}
    1. Flammer J, Kitazawa Y, Bonomi L, Mills B, Fsadni M, Dorigo MT, et al. Influence of carteolol and timolol on IOP and visual fields in glaucoma: a multi‐center, double‐masked, prospective study. European Journal of Ophthalmology 1992;2(4):169‐74. - PubMed
Geyer 1988 {published data only}
    1. Geyer O, Lazar M, Novack GD, Lue JC, Duzman E. Leovbunolol compared with timolol for the control of elevated intraocular pressure. Annals of Ophthalmology 1986;18(10):289‐92. - PubMed
    1. Geyer O, Lazar M, Novack GD, Shen D, Eto CY. Levobunolol compared with timolol: a four‐year study. British Journal of Ophthalmology 1988;72(12):892‐6. - PMC - PubMed
Heijl 2000 {published data only}
    1. Bengtsson B, Heijl A. A long‐term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. Journal of Glaucoma 2005;14(2):135‐8. - PubMed
    1. Bengtsson B, Heijl A. Diurnal IOP fluctuation: Not an independent risk factor for glaucomatous visual field loss in high‐risk ocular hypertension. Graefe's Archive for Clinical & Experimental Ophthalmology 2005;243(6):513‐8. - PubMed
    1. Heijl A, Bengtsson B. Long‐term effects of timolol therapy in ocular hypertension: a double‐masked, randomised trial. Graefe's Archive for Clinical and Experimental Ophthalmology 2000;238(11):877‐83. - PubMed
Kaiser 1994 {published data only}
    1. Kaiser HJ, Flammer J, Stümpfig D, Hendrickson P. Longterm visual field follow‐up of glaucoma patients treated with beta‐blockers. Survey of Ophthalmology 1994;38(Suppl 1):S156‐60. - PubMed
Kamal 2003 {published data only}
    1. Kamal D, Garway‐Heath D, Ruben S, O'Sullivan F, Bunce C, Viswanathan A, et al. Results of the betaxolol versus placebo treatment trial in ocular hypertension. Graefes Archive for Clinical & Experimental Ophthalmology 2003;241(3):196‐203. - PubMed
Kass 1989 {published data only}
    1. Kass MA. Five‐year follow‐up study of timolol in patients at moderate risk of developing open‐angle glaucoma. Chibret International Journal of Ophthalmology 1990;7(1):5‐8.
    1. Kass MA. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: A five‐year, randomized, double‐masked, clinical trial. Transactions of the American Ophthalmological Society 1989;87:598‐618. - PMC - PubMed
    1. Kass MA, Gordon MO, Hoff MR, Parkinson JM, Kolker AE, Hart WM, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals. A randomized, double‐masked, long‐term clinical trial. Archives of Ophthalmology 1989;107(11):1590‐8. - PubMed
Kass 2002 {published data only}
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The ocular hypertension treatments study: a randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open‐angle glaucoma. Archives of Ophthalmology 2002;120(6):701‐13. - PubMed
Kitazawa 1990 {published data only}
    1. Kitazawa Y. The effect of timolol on topographic features of the optic disk in ocular hypertension. Chibret International Journal of Ophthalmology 1990;7(1):14‐7.
Leblanc 1998 {published data only}
    1. Leblanc R, Brimonidine Study Group 2. Twelve‐month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Ophthalmology 1998;105(10):1960‐7. - PubMed
    1. Melamed S, David R, Brimonidine Study Group 2. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year‐three results. Clinical Therapeutics 2000;22(1):103‐11. - PubMed
Novack 1989 {published data only}
    1. Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, Duzman E. Levobunolol compared with timolol for the long‐term control of elevated intraocular pressure. Archives of Ophthalmology 1985;103(3):379‐82. - PubMed
    1. Cinotti A, Cinotti D, Grant W, Jacobs I, Galin M, Silverstone D, et al. Levobunolol vs timolol for open‐angle glaucoma and ocular hypertension. American Journal of Ophthalmology 1985;99(1):11‐7. - PubMed
    1. Novack G, The Levobunolol Study Group. Levobunolol. A beta‐adrenoceptor antagonist effective in the long‐term treatment of glaucoma. Ophthalmology 1985;92(9):1271‐6. - PubMed
    1. Novack GD, The Levobunolol Study Group. Levobunolol: a four‐year study of efficacy and safety in glaucoma treatment. Ophthalmology 1989;96(5):642‐5. - PubMed
    1. Ober M, Scharrer A, David R, Biedner B‐Z, Novack GD, Lue JC, et al. Long‐term ocular hypotensive effect of levobunolol: results of a one‐year study. British Journal of Ophthalmology 1985;69(8):593‐9. - PMC - PubMed
Ravalico 1994 {published data only}
    1. Ravalico G, Salvetat L, Toffoli G, Pastori G, Croce M, Parodi MB. Ocular hypertension: a follow‐up study in treated and untreated patients. New Trends in Ophthalmology 1994;9(2):97‐101.
Schulzer 1991 {published data only}
    1. Chauhan BC, Drance SM, Douglas GR. The effect of long‐term intraocular pressure reduction on the differential light sensitivity in glaucoma suspects. Investigative Ophthalmology and Visual Science 1988;29(10):1478‐85. - PubMed
    1. Schulzer M, Drance SM, Douglas GR. A comparison of treated and untreated glaucoma suspects. Ophthalmology 1991;98(3):301‐7. - PubMed
Schuman 1997 {published data only}
    1. Schuman JS, Brimonidine Study Group. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Survey of Ophthalmology 1996;41(Suppl 1):S27‐S37. - PubMed
    1. Schuman JS, Horwitz B, Choplin NT, David R, Albracht D, Chen K, Brimonidine Study Group. A 1‐year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Archives of Ophthalmology 1997;115(7):847‐52. - PubMed
Schwartz 1995 {published data only}
    1. Schwartz B, Lavin P, Takamoto T, Araujo DF, Smits G. Decrease of optic disc cupping and pallor of ocular hypertensives with timolol therapy. Acta Ophthalmologica Scandinavica 1995;73(Suppl 215):5‐21. - PubMed
    1. Schwartz B, Takamoto T, Lavin P, Smits G. Increase of retinal nerve fiber thickness in ocular hypertensives with timolol therapy. Acta Ophthalmologica Scandinavica 1995;73(Suppl 215):22‐32. - PubMed
Sponsel 1987 {published data only}
    1. Dallas NL, Sponsel WE, Hobley AJ. A comparative evaluation of timolol maleate and pilocarpine in the treatment of chronic open angle glaucoma. Eye 1988;2(Pt 3):243‐9. - PubMed
    1. Sponsel WE. Timolol vs pilocarpine in open angle glaucoma: the observation of significant differences in visual field response in patients with clinically equivalent IOP control. Chibret International Journal of Ophthalmology 1987;5(3):50‐6.
Tsai 2005 {published data only}
    1. Tsai JC, Chang HW. Comparison of the effects of brimonidine 0.2% and timolol 0.5% on retinal nerve fiber layer thickness in ocular hypertensive patients: A prospective, unmasked study. Journal of Ocular Pharmacology and Therapeutics 2005;21(6):475‐82. - PubMed
Vogel 1992 {published data only}
    1. Vogel R, Crick RP, Mills KB, Reynolds PM, Sass W, Clineschmidt CM, et al. Effect of timolol versus pilocarpine on visual field progression in patients with primary open‐angle glaucoma. Ophthalmology 1992;99(10):1505‐11. - PubMed
Watson 2001 {published data only}
    1. Watson PG, Barnet MF, Parker V, Haybittle J. A 7‐year prospective comparative study of three topical beta‐blockers in the management of primary open angle glaucoma. British Journal of Ophthalmology 2001;85(8):962‐8. - PMC - PubMed
    1. Watson PG, Barnett MF, Parker V, Haybittle J, Fellman R. A 7‐year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Evidence Based Eye Care 2002;3(3):144‐5. - PMC - PubMed
Wishart 1992 {published data only}
    1. Wishart P K, Batterbury M. Ocular hypertension: correlation of anterior chamber angle width and risk of progression to glaucoma. Eye 1992;6(Pt 3):248‐56. - PubMed

References to studies excluded from this review

Araie 2003 {published data only}
    1. Araie M, Azuma I, Kitazawa Y. Influence of topical betaxolol and timolol on visual field in Japanese open‐angle glaucoma patients. Japanese Journal of Ophthalmology 2003;47(2):199‐207. - PubMed
EMGT 1999 {published data only}
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 2002;120(10):1268‐79. - PubMed
    1. Hyman LG, Komaroff E, Heijl A, Bengtsson B, Leske MC. Treatment and vision‐related quality of life in early manifest glaucoma trial. Ophthalmology 2005;112(9):1505‐13. - PubMed
    1. Leske MC, Heijl A, Hyman L, Bengsson B, Early Manifest Glaucoma Trial. Early manifest glaucoma trial. Design and baseline data. Ophthalmology 1999;106(11):2144‐53. - PubMed
    1. Leske MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Current Opinion in Ophthalmology 2004;15(2):102‐6. - PubMed
Holmin 1988 {published data only}
    1. Holmin C, Thorburn W, Krakau CE. Treatment versus no treatment in chronic open angle glaucoma. Acta Ophthalmologica 1988;66(2):170‐3. - PubMed
Vainio 1999 {published data only}
    1. Vainio Jylha E, Vuori ML. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: a 2‐year follow‐up study. Graefes Archive for Clinical & Experimental Ophthalmology 1999;237(2):100‐4. - PubMed
    1. Vainio‐Jylhä E, Vuori ML, Nummelin K. Progression of retinal nerve fibre layer damage in betaxolol‐ and timolol‐treated glaucoma patients. Acta Ophthalmologica Scandinavica 2002;80(5):495‐500. - PubMed

References to studies awaiting assessment

CGSG 2006 {published data only}
    1. Canadian Glaucoma Study Group. Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. Canadian Journal of Ophthalmology 2006;41(5):566‐75. - PubMed
Hommer 2007 {published data only}
    1. Hommer A, Ganfort Investigators Group I. A double‐masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03% timolol 0.5% with non‐fixed combination use in patients with glaucoma or ocular hypertension. European Journal of Ophthalmology 2007;17(1):53‐62. - PubMed
Kanno 2006a {published data only}
    1. Kanno M, Araie M, Masuda K, Takase M, Kitazawa Y, Shiose Y, et al. Phase III long‐term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open‐angle glaucoma and ocular hypertension. Arzneimittel‐Forschung 2006;56(11):729‐34. - PubMed
Kanno 2006b {published data only}
    1. Kanno M, Araie M, Masuda K, Takase M, Kitazawa Y, Shiose Y, et al. Phase III long‐term study and comparative clinical study of nipradilol ophthalmic solution in patients with primary open‐angle glaucoma and ocular hypertension. Part 2. Arzneimittel‐Forschung 2006;56(12):820‐5. - PubMed
Noecker 2007 {published data only}
    1. Noecker RJ, Awadallah NS, Kahook MY. Travoprost 0.004% imolol 0.5% fixed combination. Drugs of Today 2007;43(2):77‐83. - PubMed
Schmier 2006 {published data only}
    1. Schmier JK, Halpern MT, Covert DW, Robin AL. Travoprost versus latanoprost combinations in glaucoma: economic evaluation based on visual field deficit progression. Current Medical Research & Opinion 2006;22(9):1737‐43. - PubMed
Sherwood 2006 {published data only}
    1. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, et al. Twice‐daily 0.2% brimonidine‐0.5% timolol fixed‐combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12‐month randomized trial. Archives of Ophthalmology 2006;124(9):1230‐8. - PubMed
Whitson 2006 {published data only}
    1. Whitson JT, Ochsner KI, Moster MR, Sullivan EK, Andrew RM, Silver LH, et al. The safety and intraocular pressure‐lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium‐1. Ophthalmology 2006;113(8):1333‐9. - PubMed

Additional references

Armaly 1980
    1. Armaly MF, Krueger DE, Maunder L, Becker B, Hetherington J Jr, Kolker AE, et al. Biostatistical analysis of the collaborative glaucoma study. I. Summary report of the risk factors for glaucomatous visual‐field defects. Archives of Ophthalmology 1980;98(12):2163‐71. - PubMed
Caprioli 1998
    1. Caprioli J. The treatment of normal‐tension glaucoma. American Journal of Ophthalmology 1998;126(4):578‐81. - PubMed
CNTGS 1998
    1. Collaborative Normal Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal‐tension glaucoma. American Journal of Ophthalmology 1998;126(4):498‐505. - PubMed
Diggory 1998
    1. Diggory P, Cassels‐Brown A, Vail A, Hillman JS. Randomised, controlled trial of spirometric changes in elderly people receiving timolol or betaxolol as initial treatment for glaucoma. British Journal of Ophthalmology 1998;82(2):146‐9. - PMC - PubMed
Gandolfi 2005
    1. Gandolfi SA, Ghetta A, Cimino L, Mora P, Sangermani C, Tardini MG. Bronchial reactivity in healthy individuals undergoing long‐term topical treatment with beta‐blockers. Archives of Ophthalmology 2005;123(1):135‐8. - PubMed
Glanville 2006
    1. Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6. - PMC - PubMed
Higgins 2006a
    1. Higgins JPT, Green S, editors. Assessment of study quality. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 6]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
Higgins 2006b
    1. Higgins JPT, Green S, editors. Collecting data. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006; Section 7]. In: The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd.
Maier 2005
    1. Maier PC, Funk J, Schwarzer G, Antes G, Falck‐Ytter Y. Treatment of ocular hypertension and open angle glaucoma: meta‐analysis of randomized controlled trials. BMJ 2005;331(7509):134. - PMC - PubMed
Ontoso 1997
    1. Aguinaga‐Ontoso I, Guillen‐Grima F, Aguinaga‐Ontoso E, Fernandez‐Fernandez LR. Does medical treatment of mild intraocular hypertension prevent glaucoma?. European Journal of Epidemiology 1997;13(1):19‐23. - PubMed
Quigley 1983
    1. Quigley HA, Hohmann RM, Addicks EM, Massof RW, Green W. Morphologic changes in the lamina cribrosa correlated with neural loss in open‐angle glaucoma. American Journal of Ophthalmology 1983;95(5):673‐91. - PubMed
Quigley 2005
    1. Quigley HA, Miglior S, Pfeiffer N, Zeyen T, Cunha‐Vaz J, Torri V, et al. European glaucoma prevention study. Authors' reply. Ophthalmology 2005; Vol. 112, issue 9:1642‐5.
Rossetti 1993
    1. Rossetti L, Marchetti I, Orzalesi N, Scorpiglione N, Torri V, Liberati A. Randomized clinical trials on medical treatment of glaucoma: are they appropriate to guide clinical practice?. Archives of Ophthalmology 1993;111(1):96‐103. - PubMed
Schulzer 1990
    1. Schulzer M, Drance SM, Carter CJ, Brooks DE, Douglas DE, Lau W. Biostatistical evidence for two distinct chronic open‐angle glaucoma populations. British Journal of Ophthalmology 1990;74(4):196‐200. - PMC - PubMed
Sycha 2005
    1. Sycha T, Vass C, Findl O, Bauer P, Groke I, Schmetterer L, et al. Interventions for normal tension glaucoma. Cochrane Database of Systematic Reviews 2005, Issue 1. [Art. No.: CD002222. DOI: 10.1002/14651858.CD002222.] - PubMed
Takamoto 1985
    1. Takamoto T, Schwartz B. Reproducibility of photogrammetric optic disc cup measurements. Investigative Ophthalmology and Visual Science 1985;26(6):814‐7. - PubMed
Waldock 2000
    1. Waldock A, Snape J, Graham CM. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients. British Journal of Ophthalmology 2000;84(7):710‐3. - PMC - PubMed
Wiysonge 2006
    1. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta‐blockers for hypertension. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD002003. DOI: 10.1002/14651858.CD002003.pub2] - PubMed

MeSH terms

Substances